OS Therapies Advances OST-HER2 Regulatory Submissions for Osteosarcoma Treatment
OS Therapies progresses toward Accelerated Approval for OST-HER2 in osteosarcoma, with FDA elevating meeting status and global regulatory submissions on track for Q1 2026.